0 9 Inducible inducible JJ 10 17 nuclear nuclear JJ 18 24 factor factor NN 25 32 binding bind VBG 33 35 to to TO 36 39 the the DT 40 45 kappa kappa NN 46 47 B b NN 48 56 elements element NNS 57 59 of of IN 60 63 the the DT 64 69 human human JJ 70 86 immunodeficiency immunodeficiency NN 87 92 virus virus NN 93 101 enhancer enhancer NN 102 104 in in IN 105 106 T t NN 107 112 cells cell NNS 113 116 can can MD 117 119 be be VB 120 127 blocked block VBN 128 130 by by IN 131 142 cyclosporin cyclosporin NN 143 144 A a NN 145 147 in in IN 148 149 a a DT 150 166 signal-dependent signal-dependent JJ 167 173 manner manner NN 173 174 . . . 176 187 Cyclosporin Cyclosporin NNP 188 189 A A NNP 190 191 ( ( ( 191 194 CsA CsA NNP 194 195 ) ) ) 196 198 is be VBZ 199 206 thought think VBN 207 209 to to TO 210 215 exert exert VB 216 219 its its PRP$ 220 237 immunosuppressive immunosuppressive JJ 238 245 effects effect NNS 246 248 by by IN 249 259 inhibiting inhibit VBG 260 263 the the DT 264 274 expression expression NN 275 277 of of IN 278 279 a a DT 280 288 distinct distinct JJ 289 292 set set NN 293 295 of of IN 296 306 lymphokine lymphokine NN 307 312 genes gene NNS 313 318 which which WDT 319 322 are be VBP 323 330 induced induce VBN 331 335 upon upon IN 336 342 T-cell t-cell NN 343 353 activation activation NN 353 354 , , , 355 360 among among IN 361 365 them them PRP 366 369 the the DT 370 374 gene gene NN 375 381 coding cod VBG 382 385 for for IN 386 399 interleukin-2 interleukin-2 NN 399 400 . . . 401 403 In in IN 404 412 addition addition NN 412 413 , , , 414 417 the the DT 418 428 activation activation NN 429 431 of of IN 432 435 the the DT 436 441 human human JJ 442 458 immunodeficiency immunodeficiency NN 459 464 virus virus NN 465 466 ( ( ( 466 469 HIV HIV NNP 469 470 ) ) ) 471 473 is be VBZ 474 483 partially partially RB 484 494 suppressed suppress VBN 494 495 . . . 496 498 To to TO 499 505 better well RBR 506 516 understand understand VB 517 520 the the DT 521 530 molecular molecular JJ 531 541 mechanisms mechanism NNS 542 552 underlying underlie VBG 553 564 suppression suppression NN 565 567 by by IN 568 571 CsA CsA NNP 571 572 , , , 573 575 we we PRP 576 580 have have VBP 581 593 investigated investigate VBN 594 597 the the DT 598 605 effects effect NNS 606 608 of of IN 609 613 this this DT 614 618 drug drug NN 619 621 on on IN 622 635 transcription transcription NN 636 643 factors factor NNS 644 646 in in IN 647 648 T t NN 649 654 cells cell NNS 654 655 . . . 656 660 Here here RB 661 663 we we PRP 664 670 report report VBP 671 675 that that IN 676 679 the the DT 680 689 formation formation NN 690 692 of of IN 693 696 two two CD 697 705 distinct distinct JJ 706 723 mitogen-inducible mitogen-inducible JJ 724 735 DNA-binding dna-binding JJ 736 745 complexes complex NNS 745 746 , , , 747 750 the the DT 751 756 kappa kappa NN 757 758 B b NN 759 766 complex complex NN 767 773 within within IN 774 777 the the DT 778 781 HIV HIV NNP 782 790 enhancer enhancer NN 791 794 and and CC 795 798 the the DT 799 805 NFAT-1 nfat-1 NN 806 813 complex complex NN 814 820 within within IN 821 824 the the DT 825 838 interleukin-2 interleukin-2 NN 839 847 enhancer enhancer NN 847 848 , , , 849 851 is be VBZ 852 861 inhibited inhibit VBN 862 864 in in IN 865 868 the the DT 869 877 presence presence NN 878 880 of of IN 881 884 CsA CsA NNP 884 885 . . . 886 889 The the DT 890 895 kappa kappa NN 896 905 B-binding b-binding JJ 906 914 activity activity NN 915 919 with with IN 920 923 the the DT 924 927 HIV HIV NNP 928 936 enhancer enhancer NN 937 939 is be VBZ 940 949 inhibited inhibit VBN 950 954 only only RB 955 957 if if IN 958 960 it it PRP 961 963 is be VBZ 964 973 activated activate VBN 974 977 via via IN 978 981 the the DT 982 989 mitogen mitogen NN 990 1008 phytohemagglutinin phytohemagglutinin NN 1009 1016 whereas whereas IN 1017 1024 phorbol phorbol NN 1025 1034 myristate myristate NN 1035 1051 acetate-mediated acetate-mediated JJ 1052 1062 activation activation NN 1063 1065 is be VBZ 1066 1076 completely completely RB 1077 1088 insensitive insensitive JJ 1089 1091 to to TO 1092 1095 the the DT 1096 1100 drug drug NN 1100 1101 . . . 1102 1106 This this DT 1107 1115 suggests suggest VBZ 1116 1117 a a DT 1118 1123 model model NN 1124 1126 in in IN 1127 1132 which which WDT 1133 1145 functionally functionally RB 1146 1163 indistinguishable indistinguishable JJ 1164 1169 kappa kappa NN 1170 1171 B B NNP 1172 1181 complexes complex NNS 1182 1185 can can MD 1186 1188 be be VB 1189 1198 activated activate VBN 1199 1202 via via IN 1203 1206 two two CD 1207 1215 separate separate JJ 1216 1224 pathways pathway NNS 1225 1227 of of IN 1228 1234 signal signal NN 1235 1247 transduction transduction NN 1248 1263 distinguishable distinguishable JJ 1264 1266 by by IN 1267 1270 CsA CsA NNP 1270 1271 . . .